查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1930162

全球转移性去势抗性前列腺癌治疗市场：市场规模、占有率、成长率、产业分析、依类型、应用和地区划分的考察、未来预测（2026-2034）

Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 278 Pages | 商品交期: 请询问到货日

价格

转移性去势抗性前列腺癌（mCRPC）治疗市场成长因子

受晚期前列腺癌发病率上升和对有效治疗方案需求不断成长的推动，全球 mCRPC 治疗市场正处于快速成长阶段。该市场在2025年的估值为 210.4亿美元，预计到2026年将成长至 290.8亿美元，并在2034年达到 918.5亿美元，预测期内年复合成长率（CAGR）为 15.46%。北美在2025年占据市场主导地位，市场占有率高达 87.63%。这得益于先进的医疗基础设施、强有力的偿付政策和广泛的研发活动。

转移性去势抗性前列腺癌（mCRPC）是一种晚期前列腺癌，其肿瘤不再对雄性激素剥夺疗法（ADT）完全敏感，并可转移至骨骼、淋巴结、肝臟、肺部和脑部。这种癌症的侵袭性强，且发病率和死亡率高，因此迫切需要新的治疗方法。根据世界癌症研究基金会统计，2022年全球将新增约 146万例癌症病例，凸显了对有效治疗方法日益成长的需求。

市场驱动因素

市场成长主要受以下关键因素驱动：

  • 强大的药物研发管线：製药公司积极开发新一代雄性激素受体抑制剂、PARP 抑制剂和 CYP17 抑制剂，以应对治疗抗药性前列腺癌的挑战。
  • 合作与伙伴关係：例如，2022年 7月，Merck & Co., Inc.与 Orion Corporation共同开发了 CYP11A1 抑制剂 opevesostat（MK-5684/ODM-208），用于治疗转移性去势抗性前列腺癌（mCRPC）。
  • 治疗进展：创新联合疗法的引进，例如 PARP 抑制剂和 AR 抑制剂的联合疗法，显着改善了治疗效果，并克服了对雄激素剥夺疗法（ADT）的抗药性。

市场限制与挑战

儘管成长趋势良好，但仍有几个因素限制了市场扩张：

  • 荷尔蒙疗法抗药性：随着时间的推移，前列腺癌细胞会适应雄性激素剥夺疗法，这可能会降低传统疗法的疗效。雄性激素受体路径中的突变会进一步促进抗药性的产生。
  • 不良反应：ZYTIGA（abiraterone）和enzalutamide等药物与关节肿胀、低血钾、水肿、腹泻和心血管风险有关，这些都可能影响治疗中断和患者依从性。

市场机会

  • 诊断性放射治疗的兴起：将诊断影像与标靶治疗相结合，可以实现个人化治疗，在提高疗效的同时最大限度地减少副作用。例如，Clarity Pharmaceuticals 于2023年 11月启动了一项针对 mCRP 患者的64Cu/67Cu-SAR-bisPSMA 的I/IIa 期临床试验。
  • 联合疗法的日益普及：Pfizer公司于2024年 10月启动的TALAPRO-2 试验等研究表明，PARP 抑制剂和雄激素受体抑制剂联合用药可提高患者的存活率。

市场区隔分析

依药物类别

  • 雄性激素受体抑制剂因其在抑制睪固酮介导的癌症生长方面的作用而占据市场主导地位。
  • 由于新药核准和合作关係的建立，促性腺激素释放激素促效剂、促性腺激素释放激素受体拮抗剂、微管抑制剂和PARP抑制剂预计将保持稳定成长。

依给药途径

  • 口服疗法因其便利性以及患者依从性提高而占据主导地位。
  • 肠外疗法正透过创新性临床试验而发展，例如POINT Biopharma的Actinium-225（2024年4月上市）。

依疗法

  • 荷尔蒙疗法占据主导地位，这得益于雄激素剥夺疗法的广泛应用以及醋酸阿比特龙等仿製药的普及。
  • 标靶治疗和免疫疗法领域扩展，而化疗的市场占有率则因副作用而萎缩。

依通路

  • 由于医疗基础设施完善，医院药局是主流管道。
  • 零售药局和线上药局因其便利性和可近性而不断发展。

区域洞察

  • 北美：到2025年，北美市场规模将达到113.1亿美元，这得益于美国和加拿大强大的医疗保健体系、完善的偿付政策以及研发投入。
  • 欧洲：宣传活动的加强和新型诊断工具的出现推动市场成长。例如，剑桥大学研发的一种新型 "超级检测" （于2025年2月推出）能够实现早期检测。
  • 亚太地区：该地区将以13.6%的年复合成长率实现最快成长，主要受前列腺癌发病率上升和研究经费投入增加的推动。
  • 拉丁美洲、中东和非洲：由于政府主导的措施不断加强以及癌症治疗中心的扩建，预计该地区将实现温和成长。

主要参与者趋势

Pfizer Inc.、Johnson & Johnson Services, Inc.、Astellas Pharma Inc.、AbbVie Inc.、AstraZeneca等主要参与者凭藉其丰富的产品组合、监管审批、合作伙伴关係和新产品发布，引领着市场。主要趋势包括：

  • 2023年8月：Johnson & Johnson的AKEEGA（niraparib + abiraterone）获得FDA批准用于治疗转移性去势抗性前列腺癌（mCRPC）。
  • 2023年6月：AstraZeneca的Lynparza获准用于治疗携带BRCA突变的患者。
  • 2022年12月：Novartis公司的Purvict获得欧盟委员会批准，作为一种标靶放射性配体疗法。

目录

第1章 引言

第2章 执行摘要

第3章 市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场趋势

第4章 主要考察

  • 2025年主要国家及地区摄护腺癌盛行率
  • 主要公司产品线分析
  • 替代疗法概述
  • 市场主要新创企业
  • 主要公司新产品发布
  • 主要产业发展动态（併购、合作等）
  • 新冠疫情的影响市场

第5章 全球转移性去势抗性前列腺癌治疗市场分析：洞察与预测（2021-2034）

  • 市场分析、洞察与预测：依药物类别划分
    • 雄性激素受体抑制剂
    • 微管抑制剂
    • 促性腺激素释放激素（GnRH）促效剂
    • 促性腺激素释放激素（GnRH）受体拮抗剂
    • 其他
  • 市场分析、洞察与预测：依给药途径划分
    • 口服
    • 肠外给药
  • 市场分析、洞察与预测：依疗法划分
    • 化疗
    • 荷尔蒙疗法
    • 标靶治疗治疗
    • 免疫疗法
  • 市场分析、洞察与预测：依通路划分
    • 医院药房
    • 药局及零售药房
    • 线上药房
  • 市场分析、洞察与预测：依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第6章 北美转移性去势抗性前列腺癌治疗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第7章 欧洲转移性去势抗性前列腺癌市场分析治疗市场：洞察与预测（2021-2034）

  • 依国家划分
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪的纳维亚
    • 欧洲其他地区

第8章 亚太地区转移性去势抗性前列腺癌治疗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 东南亚
    • 亚太其他地区

第9章 拉丁美洲转移性去势抗性前列腺癌治疗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 其他拉丁美洲国家

第10章 中东与非洲转移性去势抗性前列腺癌治疗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • GCC国家
    • 南非
    • 其他中东和非洲国家

第11章 竞争分析

  • 全球市场占有率分析（2025）
  • 公司简介
    • Astellas Pharma Inc.
    • Pfizer Inc.
    • Johnson &Johnson Services, Inc.
    • Sanofi
    • Ferring Pharmaceuticals Inc.
    • Sumitomo Pharma Co., Ltd.（Myovant Sciences GmbH）
    • AbbVie Inc.
    • AstraZeneca
    • Tolmar, Inc.
    • Dendreon Pharmaceuticals LLC.
    • Bayer AG
Product Code: FBI112690

Growth Factors of metastatic castration-resistant prostate cancer (mCRPC) therapeutics Market

The global metastatic castration-resistant prostate cancer (mCRPC) therapeutics market is on a rapid growth trajectory, driven by the rising prevalence of advanced prostate cancer and the increasing demand for effective treatment options. The market was valued at USD 21.04 billion in 2025, projected to grow to USD 29.08 billion in 2026, and is expected to reach USD 91.85 billion by 2034, reflecting a CAGR of 15.46% during the forecast period. North America dominated the market in 2025, holding a 87.63% share, supported by advanced healthcare infrastructure, strong reimbursement policies, and extensive research and development activities.

mCRPC is an advanced form of prostate cancer where tumors no longer fully respond to androgen deprivation therapy (ADT) and may spread to bones, lymph nodes, liver, lungs, and the brain. The aggressive nature of this cancer, combined with high morbidity and mortality, creates an urgent need for novel therapeutics. According to the World Cancer Research Fund, approximately 1.46 million new cancer cases were registered worldwide in 2022, emphasizing the growing demand for effective treatments.

Market Drivers

The market growth is propelled by several key factors:

  • Robust drug pipelines: Pharmaceutical companies are actively developing next-generation androgen receptor inhibitors, PARP inhibitors, and CYP17 inhibitors to address the challenges of treatment-resistant prostate cancer.
  • Collaborations and partnerships: For instance, in July 2022, Merck & Co., Inc. and Orion Corporation co-developed opevesostat (MK-5684/ODM-208), a CYP11A1 inhibitor for mCRPC.
  • Therapeutic advancements: The launch of innovative combination therapies, such as pairing PARP inhibitors with AR inhibitors, significantly enhances treatment outcomes and combats resistance to ADT.

Market Restraints and Challenges

Despite the positive growth trajectory, several factors limit market expansion:

  • Resistance to hormonal therapy: Over time, prostate cancer cells may adapt to androgen deprivation, reducing the effectiveness of conventional treatments. Mutations in androgen receptor pathways further contribute to resistance.
  • Adverse side effects: Drugs like ZYTIGA (abiraterone) and enzalutamide are associated with joint swelling, hypokalemia, edema, diarrhea, and cardiovascular risks, which may lead to discontinuation and impact patient compliance.

Market Opportunities

  • Emergence of radiotheranostics: Combining diagnostic imaging with targeted therapy allows personalized treatment, improving efficacy while minimizing side effects. For example, in November 2023, Clarity Pharmaceuticals initiated a Phase I/IIa trial for 64Cu/67Cu-SAR-bisPSMA in mCRPC patients.
  • Growing adoption of combination therapies: Initiatives like Pfizer's TALAPRO-2 study in October 2024 show improved survival outcomes using PARP inhibitors with androgen receptor inhibitors.

Segmentation Analysis

By Drug Class

  • Androgen receptor inhibitors dominate the market due to their role in blocking testosterone-driven cancer growth.
  • GnRH agonists, GnRH receptor antagonists, microtubule inhibitors, and PARP inhibitors are projected to grow steadily due to new approvals and collaborations.

By Route of Administration

  • Oral therapies dominate due to convenience, patient adherence, and better compliance.
  • Parenteral therapies are growing through innovative clinical trials, such as Actinium-225 by POINT Biopharma (April 2024).

By Therapy

  • Hormonal therapy leads, supported by widespread adoption of androgen deprivation therapy and availability of generics like Abiraterone Acetate.
  • Targeted therapy and immunotherapy segments are expanding, while chemotherapy holds a smaller share due to side effects.

By Distribution Channel

  • Hospital pharmacies dominate, owing to advanced healthcare infrastructure.
  • Retail and online pharmacies are growing due to convenience and accessibility.

Regional Insights

  • North America: Market size USD 11.31 billion in 2025, supported by the U.S. and Canada's robust healthcare systems, reimbursement policies, and R&D.
  • Europe: Rising awareness campaigns and new diagnostic tools propel growth. For example, a new 'super test' developed in Cambridge (February 2025) enables early detection.
  • Asia Pacific: Fastest-growing region with a CAGR of 13.6%, fueled by increasing prostate cancer prevalence and research funding initiatives.
  • Latin America & Middle East & Africa: Moderate growth is anticipated, with increased government initiatives and expansion of cancer care centers.

Key Industry Players

Leading companies such as Pfizer Inc., Johnson & Johnson Services, Inc., Astellas Pharma Inc., AbbVie Inc., and AstraZeneca dominate the market through extensive product portfolios, regulatory approvals, collaborations, and new launches. Notable developments include:

  • August 2023: FDA approval of AKEEGA (niraparib + abiraterone) for mCRPC by Johnson & Johnson.
  • June 2023: AstraZeneca's Lynparza (olaparib) approved for patients with BRCA mutations.
  • December 2022: Novartis' Pluvicto approved by European Commission as targeted radioligand therapy.

Conclusion

The global metastatic castration-resistant prostate cancer therapeutics market is projected to grow from USD 21.04 billion in 2025 to USD 91.85 billion by 2034, at a CAGR of 15.46%. Market expansion is driven by the rising prevalence of advanced prostate cancer, robust R&D pipelines, innovative combination therapies, and emerging radiotheranostics. North America dominates, while Asia Pacific represents the fastest-growing region. Leading companies' strategic initiatives, product launches, and research collaborations are expected to sustain market growth and enhance treatment outcomes for mCRPC patients globally.

Segmentation By Drug Class

  • Androgen Receptor Inhibitors
  • Microtubule Inhibitors
  • Gonadotropin Releasing Hormone (GnRH) Agonist
  • Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  • Others

By Route of Administration

  • Oral
  • Parenteral

By Therapy

  • Chemotherapy
  • Hormonal Therapy
  • Targeted therapy
  • Immunotherapy

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

By Geography

  • North America (By Drug Class, By Route of Administration, By Therapy, By Distribution Channel, and By Country)
    • U.S.
    • Canada
  • Europe (By Drug Class, By Route of Administration, By Therapy, By Distribution Channel, and By Country/Sub-Region)
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific (By Drug Class, By Route of Administration, By Therapy, By Distribution Channel, and By Country/Sub-Region)
    • Japan
    • China
    • India
    • Australia
    • Rest of Asia Pacific
  • Latin America (By Drug Class, By Route of Administration, By Therapy, By Distribution Channel, and By Country/Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa ( By Drug Class, By Route of Administration, By Therapy, By Distribution Channel, and By Country/Sub-Region)
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Prostate Cancer - by Key Countries/Regions, 2025
  • 4.2. Pipeline Analysis, by Key Players
  • 4.3. Overview of Alternative Therapies
  • 4.4. Key Start-ups in the Market
  • 4.5. New Product Launches, by Key Players
  • 4.6. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.7. Impact of COVID-19 on the Market

5. Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug Class
    • 5.1.1. Androgen Receptor Inhibitors
    • 5.1.2. Microtubule Inhibitors
    • 5.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 5.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 5.1.5. Others
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Oral
    • 5.2.2. Parenteral
  • 5.3. Market Analysis, Insights and Forecast - By Therapy
    • 5.3.1. Chemotherapy
    • 5.3.2. Hormonal Therapy
    • 5.3.3. Targeted therapy
    • 5.3.4. Immunotherapy
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital Pharmacies
    • 5.4.2. Drug Stores & Retail Pharmacies
    • 5.4.3. Online Pharmacies
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug Class
    • 6.1.1. Androgen Receptor Inhibitors
    • 6.1.2. Microtubule Inhibitors
    • 6.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 6.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 6.1.5. Others
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Oral
    • 6.2.2. Parenteral
  • 6.3. Market Analysis, Insights and Forecast - By Therapy
    • 6.3.1. Chemotherapy
    • 6.3.2. Hormonal Therapy
    • 6.3.3. Targeted therapy
    • 6.3.4. Immunotherapy
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital Pharmacies
    • 6.4.2. Drug Stores & Retail Pharmacies
    • 6.4.3. Online Pharmacies
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug Class
    • 7.1.1. Androgen Receptor Inhibitors
    • 7.1.2. Microtubule Inhibitors
    • 7.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 7.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 7.1.5. Others
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Oral
    • 7.2.2. Parenteral
  • 7.3. Market Analysis, Insights and Forecast - By Therapy
    • 7.3.1. Chemotherapy
    • 7.3.2. Hormonal Therapy
    • 7.3.3. Targeted therapy
    • 7.3.4. Immunotherapy
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital Pharmacies
    • 7.4.2. Drug Stores & Retail Pharmacies
    • 7.4.3. Online Pharmacies
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. Germany
    • 7.5.2. U.K.
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug Class
    • 8.1.1. Androgen Receptor Inhibitors
    • 8.1.2. Microtubule Inhibitors
    • 8.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 8.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 8.1.5. Others
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Oral
    • 8.2.2. Parenteral
  • 8.3. Market Analysis, Insights and Forecast - By Therapy
    • 8.3.1. Chemotherapy
    • 8.3.2. Hormonal Therapy
    • 8.3.3. Targeted therapy
    • 8.3.4. Immunotherapy
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital Pharmacies
    • 8.4.2. Drug Stores & Retail Pharmacies
    • 8.4.3. Online Pharmacies
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug Class
    • 9.1.1. Androgen Receptor Inhibitors
    • 9.1.2. Microtubule Inhibitors
    • 9.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 9.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 9.1.5. Others
  • 9.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.2.1. Oral
    • 9.2.2. Parenteral
  • 9.3. Market Analysis, Insights and Forecast - By Therapy
    • 9.3.1. Chemotherapy
    • 9.3.2. Hormonal Therapy
    • 9.3.3. Targeted therapy
    • 9.3.4. Immunotherapy
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital Pharmacies
    • 9.4.2. Drug Stores & Retail Pharmacies
    • 9.4.3. Online Pharmacies
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Drug Class
    • 10.1.1. Androgen Receptor Inhibitors
    • 10.1.2. Microtubule Inhibitors
    • 10.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 10.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 10.1.5. Others
  • 10.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.2.1. Oral
    • 10.2.2. Parenteral
  • 10.3. Market Analysis, Insights and Forecast - By Therapy
    • 10.3.1. Chemotherapy
    • 10.3.2. Hormonal Therapy
    • 10.3.3. Targeted therapy
    • 10.3.4. Immunotherapy
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Drug Stores & Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Astellas Pharma Inc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Pfizer Inc.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Johnson & Johnson Services, Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Sanofi
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Ferring Pharmaceuticals Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Sumitomo Pharma Co., Ltd. (Myovant Sciences GmbH)
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. AbbVie Inc.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. AstraZeneca
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Tolmar, Inc.
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. Dendreon Pharmaceuticals LLC.
      • 11.2.10.1. Overview
      • 11.2.10.2. Products
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)
    • 11.2.11. Bayer AG
      • 11.2.11.1. Overview
      • 11.2.11.2. Products
      • 11.2.11.3. SWOT Analysis
      • 11.2.11.4. Recent Developments
      • 11.2.11.5. Strategies
      • 11.2.11.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 2: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 3: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy, 2021-2034
  • Table 4: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel 2021-2034
  • Table 5: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 6: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 7: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 8: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy, 2021-2034
  • Table 9: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel 2021-2034
  • Table 10: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 11: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 12: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 13: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy, 2021-2034
  • Table 14: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel 2021-2034
  • Table 15: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 17: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 18: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy, 2021-2034
  • Table 19: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel 2021-2034
  • Table 20: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 22: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 23: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel 2021-2034
  • Table 24: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy, 2021-2034
  • Table 25: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 26: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 27: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 28: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy, 2021-2034
  • Table 29: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel 2021-2034
  • Table 30: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2025 & 2034
  • Figure 3: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 4: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2025 & 2034
  • Figure 5: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 6: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Region, 2025 & 2034
  • Figure 7: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 8: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2025
  • Figure 9: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 10: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 11: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 12: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2025
  • Figure 13: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 14: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 15: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), By Country, 2025 & 2034
  • Figure 16: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), By Country, 2025
  • Figure 17: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 18: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2025
  • Figure 19: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 20: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 21: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 22: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2025
  • Figure 23: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 24: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 25: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 26: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 27: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 28: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2025
  • Figure 29: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 30: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 31: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 32: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2025
  • Figure 33: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion),by Distribution Channel, 2025 & 2034
  • Figure 34: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 35: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 36: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 37: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 38: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2025
  • Figure 39: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 40: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 41: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 42: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2025
  • Figure 43: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 44: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 45: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 46: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 47: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 48: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2025
  • Figure 49: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 50: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 51: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 52: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2025
  • Figure 53: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 54: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 55: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 56: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2025

Figure 57: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Share (%), By Company, 2025